| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -21,150,211 | -15,263,388 |
| Depreciation and amortization | 839,242 | 571,859 |
| Stock-based compensation expense | 1,956,078 | 1,455,493 |
| Common stock issued for financial advisory services | 135,000 | 135,000 |
| Change in fair value of acquisition contingencies | 684,944 | 727,289 |
| Non-cash lease expense | -4,985 | -2,003 |
| Realized gain on investments | 683,365 | 641,823 |
| Loss from equity method investment | -71,163 | -15,204 |
| (gain) loss on disposition of assets | -5,004 | -9,004 |
| Provision for credit losses (recoveries of) | -22,375 | -13,248 |
| Inventory obsolescence expense (recovery) | -138,983 | -95,302 |
| Accounts receivable | -99,040 | 65,150 |
| Prepaid expenses and other assets | 69,584 | -690,010 |
| Inventory | -121,752 | -83,399 |
| Deferred revenue | 4,700 | 5,000 |
| Income taxes payable | -221,795 | 23,290 |
| Accounts payable, accrued expenses and other liabilities | -3,193,366 | -3,213,100 |
| Net cash used in operating activities | -22,937,629 | -17,033,044 |
| Purchases of property and equipment | 568,078 | 492,973 |
| Proceeds from maturities of marketable investment securities | 33,761,847 | 31,509,485 |
| Purchases of marketable securities | 6,590,939 | 6,588,577 |
| Net cash provided by investing activities | 26,602,830 | 24,427,935 |
| Issuance of common stock related to at-the-market offering, net of offering costs | 1,313,929 | 783,746 |
| Issuance of common stock related to registered direct offering, net of offering costs | 3,528,269 | - |
| Net cash provided by financing activities | 4,842,198 | 783,746 |
| Net increase (decrease) in cash and cash equivalents | 8,507,399 | 8,178,637 |
| Cash and cash equivalents at beginning of period | 2,936,544 | - |
| Cash and cash equivalents at end of period | 11,443,943 | - |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)